Evidence map›Paper›PMID 42625065›Full record

GuidelineNature reviews. Rheumatology2026

Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.

Alexandra Audemard-Verger, Evangéline Pillebout, Eva Baier, Ingeborg M Bajema, Jonathan Barratt, George Bertsias, Annette Bruchfeld, Santos Castañeda, Maria C Cid, Rosanna Coppo and 21 more

Abstract readPractice GuidelineSystematic ReviewReview
PubMed Publisher
In one paragraph

Guideline in Nature reviews. Rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Alexandra Audemard-VergerDepartment of Internal Medicine, CHU de Tours, Université de Tours, Tours, France.
Evangéline PilleboutDepartment of Nephrology, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France.
Eva BaierUniversitätsmedizin Göttingen, Göttingen, Germany.
Ingeborg M BajemaFaculty of Medical Sciences/UMCG, Groningen, Netherlands.
Jonathan BarrattDepartment of Cardiovascular Sciences, University of Leicester and Leicester General Hospital, Leicester, UK.
George BertsiasRheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Heraklion, Greece.ORCID http://orcid.org/0000-0001-5299-1406
Annette BruchfeldDepartment of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0002-9752-9941
Santos CastañedaDepartment of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain.ORCID http://orcid.org/0000-0002-7748-853X
Maria C CidDepartment of Autoimmune Diseases. Hospital Clínic de Barcelona, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (DIBAPS), Barcelona, Spain.ORCID http://orcid.org/0000-0002-4730-0938
Rosanna CoppoFondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.
Haner DireskeneliDivision of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey.ORCID http://orcid.org/0000-0003-2598-5806
Carmela ErrichielloNephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
Jürgen FloegeDivision of Nephrology and Immunology at RWTH Aachen University, Aachen, Germany.
Miguel A González-GayInstituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz, Madrid, Spain.ORCID http://orcid.org/0000-0002-7924-7406
Ahmet GülDepartment of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-8219-3720
Antoine HankardDepartment of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France.
Alojzija HočevarDepartment of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Marie JachietDepartment of Dermatology, Hôpital Saint-Louis, AP-HP, Paris, France.
Marija JelusicDepartment of Paediatric Rheumatology, University of Zagreb, School of Medicine, Zagreb, Croatia.
Noémie Jourde-ChicheDepartment of Nephrology, Hôpital de la Conception, Marseille, France.
Alfred D MahrKusnacht practice, Zurich, Switzerland.
Thomas NeumannKlinik für Innere Medizin III, University-Hospital Jena, Jena, Germany.
Louise OniDepartment of Nephrology, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, UK.
Seza ÖzenDivision of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.ORCID http://orcid.org/0000-0003-2883-7868
Alan D SalamaUCL Centre for Nephrology, Royal Free Hospital, University College London, London, UK.ORCID http://orcid.org/0000-0002-9255-9092
Cord SunderkötterDepartment of Dermatology, Universitätsklinikum Halle, Halle, Germany.
Benjamin TerrierDepartment of Internal Medicine and Clinical Immunology, Hôpital Cochin, AP-HP, Université Paris Cité, Paris, France.
Giorgio TrivioliDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0003-1578-4402
David JayneDepartment of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.ORCID http://orcid.org/0000-0002-1712-0637
Augusto VaglioNephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy. augusto.vaglio@unifi.it.ORCID http://orcid.org/0000-0002-3814-9172
collaborators of the EUGAVAS Study Group on behalf of the European Vasculitis Society (EUVAS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IgA vasculitis (IgAV) is an immune complex-mediated small-vessel vasculitis that typically affects the skin, gastrointestinal tract, kidneys and joints. Childhood-onset IgAV is a common disease and usually follows a self-limiting course, whereas adult-onset IgAV is considerably less frequent and is associated with a poorer prognosis. The diagnosis, assessment and management of adult-onset IgAV remain challenging owing to the absence of validated diagnostic criteria for adults and lack of IgAV-specific standardized disease activity scores. Short-term outcomes are mainly determined by gastrointestinal complications, whereas kidney involvement and the risk of progression to chronic kidney disease are the major determinants of long-term prognosis. The treatment of adult-onset IgAV is limited by the paucity of high-quality clinical trials and standardized therapeutic approaches. Here, we present evidence-based, multidisciplinary guidelines for the diagnosis and management of adult-onset IgAV that reflect advances in understanding of pathogenesis, differential diagnoses and treatment over the past two decades. Developed by a panel of leading European experts on the basis of systematic literature review and expert opinion, these guidelines comprise 14 recommendation statements and overarching principles that provide a structured and pragmatic clinical framework for the diagnosis, treatment and follow-up of adult-onset IgAV.

Indexed as

IgA VasculitisImmunoglobulin AVasculitisAdultAge of OnsetDiagnosis, DifferentialEvidence-Based MedicineHumansPractice Guidelines as TopicPrognosisImmunoglobulin A

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.